european Industrial Pharmacy 2011 – 2015

ISSUE 27 • DECEMBER 2015
European Industrial Pharmacy
Editorial Comment: An interested party
Piero Iamartino

Demand for OTC medicines continues to rise
Kitty Zhang
The UK over-the-counter pharmaceutical market benefits from an ageing population and changes in the healthcare system.

Pharmaceutical polymorphs and cocrystals: is the same always the same?
Liana Vella-Zarb
The recent addition of polymorphs and cocrystals to the EMA guidelines regarding classification of materials as new active substances or otherwise has inspired the formulation of a brief clarification detailing the fine line between what is equivalent and what is not, in the context of pharmaceutical polymorphs and cocrystals.

Manipulating dosage forms for children: understanding and improving practice
Roberta Richey, Utpal Shah, Matthew Peak, Jean Craig, Jim Ford, Catrin Barker, Tony Nunn and Mark Turner
Manipulation of adult medicines is frequently used to provide paediatric doses. The guideline Manipulation of Drugs Required in Children (MODRIC): A Guide for Health Professionals was produced and emphasises the lack of evidence around manipulation whilst suggesting good practices that might reduce potential risks.

Protecting medical record data
Lauren Sporck
The healthcare industry, valued at $3 trillion, has become an increasingly valuable target for cyber thieves, and in some cases, a much easier target to attack, due to their often less than adequate investment in cyber security. What is it about the healthcare industry that has captured the cyber criminal’s interest in the last few years?

News From The EIPG
Jane Nicholson

Regulatory Review

Events

Read Issue 27   

ISSUE 26 • SEPTEMBER 2015
European Industrial Pharmacy
Editorial Comment: The journey and the goal
Claude Farrugia

First-in-class innovation in the pipeline for treatment of muscular dystrophy
Angel Wong
This article examines the current Duchenne muscular dystrophy therapeutics market and trends in the developmental pipeline, with a specific focus on the first-in-class molecules that will potentially transform future muscular dystrophy treatment.

Child resistance in pharmaceutical packaging
Hung Le
This article highlights the critical role of innovation in child resistant packaging.

Getting to higher quality processes sooner – new guide helps you make a better choice of biological materials
Patrick Ginty and Ben Sheridan
To help remove the complexity from choosing materials that compose cell-based medicinal products, ‘PAS 157:2015 Evaluation of Materials of Biological Origin Used in the Production of Cell-Based Medicinal Products – Guide’ was developed by BSI, the Cell Therapy Catapult and the cell therapy industry.

In silico clinical trials: dream or certainty?
Marco Viceconti, Adriano Henney, Edwin Morley-Fletcher and Martina Contin
This September, the Avicenna Consortium, tasked by the European Commission to investigate how computer modelling might mitigate the cost of clinical trials, released its Roadmap ‘In Silico Clinical Trials: How Computer Simulation Will Transform The Biomedical Industry’.

700 génériques retirés du marché: concrètement, ça change quoi?
Hugo Jalinière, for Sciences et Avenir
Mme Isabelle Adenot, President of the French Conseil national de l’Ordre des Pharmaciens, talks to journalist Hugo Jalinière, of the French periodical Sciences et Avenir, on the impact of the EU-wide withdrawal from the market of 700 medicinal products, following an EU-wide suspension of their marketing authorisations.

Regulatory Review

Bottled Brown

News From The EIPG
Jane Nicholson

Events

Read Issue 26   

ISSUE 25 • JUNE 2015
European Industrial Pharmacy
Editorial Comment: A patient in every box
Jean Pierre Paccioni and Claude Farrugia

Raising the bar on pharma IT security
Vijay Takanti
Reduce risk and better protect business-critical pharma IT applications and data by leveraging strong authentication and identity hubs to control internal and external user access.

The Office of Pharmaceutical Quality: FDA’s new “One Quality Voice”
Gary Bird
The new Office of Pharmaceutical Quality at the USFDA promises to become FDA’s “One Quality Voice”, a fully functioning source of information for all things related to quality for US drug products.

Next in line: personalised healthcare
Wouter Laroy
Finding, validating and commercialising new and powerful biomarkers and bringing these together in syndromic panels will push the personalised healthcare model forward, research that will be driven by the introduction of new and innovating technologies.

Technological advances in rational drug design
Andreas Förster and Clemens Schulze-Briese
Hybrid photon counting pixel detectors can lead to better X-ray structures more quickly and provide optimised starting points for drug design.

The pharmaceutical pipeline for non-small cell lung cancer
Joshua Libberton
This article discusses diversity and innovation in the NSCLC treatment pipeline, as pharmaceutical companies seek to meet the needs of an increasingly segmented market.

Curing the ailing clinical trial
Dirk Meijer
It can be a costly business for a clinical trial to fail, but several indicators have been identified which can lead to early intervention and recovery.

Regulatory Review

Bottled Brown

News From The EIPG
Jane Nicholson

Events

Read Issue 25   

ISSUE 24 • MARCH 2015
European Industrial Pharmacy
Editorial Comment: A year of challenges, a year of work
Jean Pierre Paccioni

International efforts to protect patients from unsafe pharmaceuticals
Jim Dahl, Thomas T. Kubic and Marv Shepard
Industry experts, law enforcement and regulators work globally to staunch the flow of dangerous, unregulated pharmaceutical products.

Green analytical chemistry in the pharmaceutical industry
Sergio Armenta and Miguel de la Guardia
A critical evaluation of the advantages of green analytical chemistry in the pharmaceutical industry.

Planning your first year of selling in the US life sciences market
Jim Worrell
European life science companies face many hurdles to break into the US market, but with strategic planning they can land on fertile soil.

The power of drug colour
Tessa Fiorini Cohen
This paper investigates the subtle ways in which a drug’s colour can improve its efficacy.

Ireland launches an integrated 5-year pharmacy education and training programme
Maura Kinahan
This article outlines changes in pharmacy undergraduate education in Ireland with the fully integrated MPharm programme in September 2015.

EPSA Individual Mobility Project
Svetlana Kolundžić
A long-term internship project giving opportunities to gain real-time work and research experience.

Regulatory Review

Bottled Brown

News From The EIPG
Jane Nicholson

Events

Competences for industrial pharmacy practice in biotechnology – the PHAR-IN project
The PHAR-IN Consortium
The PHAR-IN Consortium has produced and evaluated a biotechnology competence framework identifying priorities in developing a course to acquire such competences.

Read Issue 24   

ISSUE 23 • DECEMBER 2014
European Industrial Pharmacy
Editorial Comment: Will they? Won’t they?
Claude Farrugia

Achieving biosimilar product approval – key success factors for development
Hideaki Nomura and Gary Trewartha
Biosimilars have attracted increasing attention over the past 10 years. This article describes key success factors for biosimilar development, such as understanding of regulatory requirements and the science of biological products.

Gazing into the crystal ball: What will the EU-FMD Safety Features Delegated Act bring?
Christoph Krähenbühl
In 2018, far reaching changes will come into force across Europe that were introduced by the EU Falsified Medicines Directive (2011/62/EU). This article examines the details and impact of the provisions of the ‘Safety Features’ Delegated Act and how these will affect the pharma supply chain across Europe and beyond.

Recent R&D breakthroughs continue to revolutionise the already dynamic hepatitis C treatment landscape
Christopher Pace
This article outlines the past and present hepatitis C virus treatment landscape, placing a particular emphasis on the most recent developments and industry trends.

Quality metrics, quality culture, quality matters!
Tom Sam and Henny Koch
This article examines measures to ensure quality throughout a medicine’s lifecycle from product design to manufacturing and distribution, emphasising the pivotal roles of patient centricity and quality culture.

Regulatory Review

Letter to the Editor

Bottled Brown

News From The EIPG
Jane Nicholson

Events

Read Issue 23   

ISSUE 22 • SEPTEMBER 2014
European Industrial Pharmacy
Editorial Comment: The shape of pharma to come
Claude Farrugia

Supplementary protection certificates: of clarity and confusion
Ian Moss
The law surrounding SPCs is difficult and uncertain. Three December 2013 judgements from Europe’s highest court clarify one issue but create several more.

Life Sciences Report 2014: Genome 2.0
Richard Gibbs
This article discusses the findings of the Marks & Clerk Life Sciences Report, which includes intellectual property trends in the genome market and patent analytics conducted in sequencing technology, personalised medicine and synthetic biology.

Pharmacopoeial harmonisation: an historical perspective
Tony Cartwright
Pharmacopoeial harmonisation has been a constant process since 1864. This article summarises some of the key achievements and suggests that the future lies in enhanced cooperation and work-sharing between the national and regional pharmacopoeias.

Regulatory Review

Bottled Brown

News From The EIPG
Jane Nicholson and Anni Svala

Events

Read Issue 22   

ISSUE 21 • JUNE 2014
European Industrial Pharmacy
Editorial Comment
Jean-Pierre Paccioni

Patients as partners in pharmaceutical development programmes
Kay Fisher
This paper details why we need to review the data sets we use in drug development to ensure that we capture the life science data which can critically influence patient outcomes.

The imperative for a new adaptive and resilient LSH supply chain
Lisa Harrington
A more resilient and adaptive supply chain model that works collaboratively with partners and provides end-to-end visibility is needed for companies to survive the complex issues that have brought an end to business as usual.

Linking industry and academia in teaching pharmaceutics (LIAT-Ph)
LIAT-Ph Consortium
The EU-funded LIAT-Ph Consortium brings together industry and academia to address the educational needs of future and current industrial pharmacists in pharmaceutical development and manufacture.

International summit on medicine shortages
Betty Chaar and Luc Besançon
This article summarises the inaugural International Summit on Medicine Shortages hosted by FIP which aimed to provide a forum to discuss the causes, impacts and solutions of medicine shortages.

Pharmaceutical firms can’t keep ignoring information risk
Phil Greenwood
Europe’s pharmaceutical firms have not yet committed to taking information risk seriously, and this article examines why they can’t continue to ignore information risk and the damaging consequences of data breaches

Regulatory Review

News From The EIPG
Jane Nicholson

Events

Read Issue 21   

ISSUE 20 • MARCH 2014
European Industrial Pharmacy
Editorial Comment
Luigi Martini

Unstandard standards
Michael Anisfeld
The need for a single worldwide accepted pharmacopoeia has been recognised for about 150 years. It seems intuitively obvious that wherever you are born, you deserve drugs meeting the same high quality standards and this was the goal behind the establishment of the International Pharmacopoeia.

In a nutshell – improving biopharmaceutical performance of oral drug products
Uwe Muenster
An active pharmaceutical ingredient needs to fulfil several criteria in order to be successfully brought to a patient in medical need, such as clinical efficacy, an acceptable safety profile and desired pharmacokinetics, and certain physicochemical properties and biopharmaceutical performance.

The young biopharmaceutical companies use and dependence on CMO/CRO
Jan Gunnar Gustafsson
The young biotech companies have a limited knowhow concerning development of pharmaceuticals. This article describes how the CMO can support biotech companies and what they should do to be successful and build a mutually beneficial relationship.

Division of liability between pharmaceutical companies and suppliers using the example of the law in the Federal Republic of Germany
Martin Wesch
Division of liability within the pharmaceutical supply chain saves money and efforts of testing. It requires a shift of duties to take care of that part of the chain where the risks arise through the manufacturing process. Sufficient insurance coverage should be in place.

Regulatory Review

News From The EIPG
Jane Nicholson

Events

Read Issue 20   

ISSUE 19 • DECEMBER 2013
European Industrial Pharmacy
Editorial Comment
Jean-Pierre Paccioni

Scale-up of spray dried amorphous solid dispersions
José Luís Santos, Paula Cordeiro and Márcio Temtem
Technologies capable of addressing solubility issues are needed in light of the many insoluble drugs in development. The authors discuss the use of stabilised amorphous solid dispersions prepared using pharmaceutical spray drying.

The Innovative Medicines Initiative OrBiTo project – developing the next generation of predictive tools for oral biopharmaceutics
Mark McAllister, Bertil Abrahamsson and Hans Lennernäs
The Innovative Medicines Initiative OrBiTo project is a collaboration between pharma, academia and specialist technology companies to enhance our understanding of absorption of orally-administered drugs from the gastrointestinal tract and apply this knowledge to predict the performance of oral formulations in patients.

Formulation technology enables the delivery of HIV medicines
Peter Timmins and Jonathan Brown
Innovative formulation technologies have been developed to overcome drug delivery challenges of treatments of HIV infection. This article describes problems of solubility, pharmacokinetics and physical material properties along with their resolution in a series of case examples.

Taking steps to implement the Falsified Medicines Directive and combat counterfeiting in Europe – the European Stakeholder Model
Richard Bergström
Falsified medicines present a public health threat at global level, with counterfeit goods threatening the health of patients in countries around the world. This article discusses measures to fight counterfeiting.

Regulatory Review

News From The EIPG
Jane Nicholson

Events

Read Issue 19   

ISSUE 18 • OCTOBER 2013
European Industrial Pharmacy
Editorial: Message from the new President, Mr Jean-Pierre Paccioni
Jean-Pierre Paccioni

From push to pull marketing in healthcare
Morten Hjelmsoe
This article describes how new technology enables customer communication to be tailored to each healthcare professional – creating personalised channels of highly relevant information.

Printing medicines
Simon Gaisford
3D printers have many potential biomedical applications and have recently been used to print unit dosage forms. This article illustrates how printing technology could revolutionise the manufacture of medicines.

Pharmacy in Norway
Wenche Gordon
The author summarises the evolution of pharmacy in Norway and how regulations and economics have contributed to the climate today.

The new GDP guidelines
Siegfried Schmitt
The author summarises and comments on the new guidelines on Good Distribution Practice of Medicinal Products for Human Use, which came into force on 8 September 2013. These guidelines apply not only to the wholesalers and manufacturers of pharmaceuticals, but also to brokers.

Competences for industrial pharmacy practice in biotechnology – the PHAR-IN project
Jeffery Atkinson, Jane Nicholson, and Bart Rombaut
This article informs on the PHAR-IN project, which is funded by the European Commission and aims to recruit pharmacy industrialists and educationalists who will propose a list of competences and outcomes required for education in biotechnology in the pharmaceutical industry.

Regulatory Review

News From The EIPG
Jane Nicholson

Events

Read Issue 18   

ISSUE 17 • JUNE 2013
European Industrial Pharmacy
Editorial: EIPG elects a new President: Martini passes the baton to Paccioni
Claude Farrugia

Stable cytochrome P450 enzymes for toxicity and metabolism testing
Bob Chaudhuri and Bill Primrose
Researchers at De Montfort University, Leicester, UK, have made a breakthrough in stabilising CYPs that could save millions on the pre-clinical and clinical stages of drug development.

Controlled environments: the new IEQ
Chuck McKinney
Demand controlled ventilation can optimise energy consumption in laboratories and cleanrooms without compromising performance or quality, thus achieving significant cost savings and greenhouse gas reduction.

Comparison of biosafety testing requirements of biologicals and vaccines
Daniel Galbraith
Failing to detect viral contamination in biologicals and vaccines can cost drug developers dear in terms of time and money. New technologies may improve our detection methods.

Bridging API manufacturing
Márcio Temtem, Filipe Neves, and Conrad Winters
Particle design can have an important effect on the performance of the final dosage form of an API. Examples of the use of microparticles and nanoparticles are shown.

Pharmacopoeial compliance
Kevin F Goode
This article serves as a general introduction to a short series on the major pharmacopoeias. The second article will describe and discuss the British Pharmacopoiea.

Regulatory Review

News From The EIPG
Jane Nicholson

Events

Read Issue 17   

ISSUE 16 • MARCH 2013
European Industrial Pharmacy
Editorial Comment
Gino Martini

Generics uptake in Europe – the impact of pricing and reimbursement policies
Joe Ridge
Results of a survey on pricing and reimbursement policies regarding generics in Europe are described and discussed.

Improving the quality of injectables
Mike Schaefers
Primary packaging, such as elastomeric closures for injectables, needs to be strictly controlled to reduce particles and the rejection of finished product.

The future of pharma? Speciation, sex and death
Brian D Smith
The author applies evolutionary theory to pharmaceutical companies, whereby they need to adapt to survive.

Working towards a standardised identification solution
Peter Belden
Identification and coding of products is essential to avoid counterfeiting and so ensuring the safety of the supply chain.

Training – doing it wrong!
Michael Anisfield
Training in Good Manufacturing Practices is not just a matter of learning the regulations but of understanding them.

Cost versus quality – the real price you could pay for ‘budget’ PV
Steve Proudlove
It may be false economy to choose a pharmacovigilance service provider based on cost rather than quality. The author suggests ways of avoiding problems.

An industry career for a young pharmacist
João da Silva Duarte
A young Portuguese pharmacist shows that with the right skills and passion, it is possible to enter the European pharmaceutical industry.

Regulatory Review
Malcolm Holmes

News From The EIPG
Jane Nicholson

Events

Read Issue 16   

ISSUE 15 • DECEMBER 2012
European Industrial Pharmacy
Editorial Comment
Gino Martini

Laboratory scale spray-drying of lactose: a review
Nina Schafroth and Marco Meuri
Lactose is widely used as an excipient for dry powder lung delivery. This article reviews recently published work in the lactose spray drying field using laboratory scale spray dryers.

Labour law and whistleblowing according to European and German legislation
Martin Wesch
Whistleblowing continues to be highly contentious especially when the employee informs the general public via the press. The author, an attorney apecialising in labour and medical law, seeks to clarify the situation.

Development of a novel intra-nasal spray product: a case history
David P Elder, Andrew C Grant, Jim Godfrey, Anna Slater, Gavin Bone and Gary Cannon
The problems of formulation as well as the design of the device are addressed by the authors in this detailed case history.

SWOT analysis using general morphological analysis: application to the specials sector for new business drivers
Nasir Hussain, Bruce Garvey and Thomas Ritchey
A major improvement of SWOT (strengths, weaknesses, opportunities and threats) by a problem structuring method is described in the content of a start-up niche generic company.

Home healthcare: it’s people not products that count
Dan Formosa
The effect of a medical device on a patient’s life should be one of the main considerations when designing a device.

Regulatory Review

News From The EIPG
Jane Nicholson

Events

Read Issue 15   

ISSUE 14 • SEPTEMBER 2012
European Industrial Pharmacy
Editorial Comment
Gino Martini

Oral insulin delivery systems
E Castellanos Ruiz, M Garcia Hierro and P Medel Torres
Oral insulin treatment may soon be a reality concludes this review of various delivery systems.

Flushing away our future
Fred Massoomi
The medicines consumed by millions daily contain ingredients that could destroy the environment and ultimately our future.

Concordance in cultural context
Malcolm E Brown
Concordance, unlike compliance, is the mutual agreement between a well-informed patient and his physician to take the prescribed treatment.

Medical devices designed with patients in mind
Steve May-Russell
Device manufacturers need to design medical devices to make them more appealing to the patient, and lead to success in the marketplace.

The EPSRC centre for innovative manufacturing in regenerative medicine
C Rogers, M Mather, F Rose, K Shakesheff and D Williams
Research in regenerative medicine requires collaboration between industrial and academic partners.

Integrating IT tools with the pharmaceutical industry and education in India
Shyamal Kalani
In order to generate a competent workforce, pharmacy education needs to incorporate IT skills and industry practices.

Book Review

Regulatory Review

Pharmaceutical Forum

News From The EIPG
Jane Nicholson

Events

Read Issue 14   

ISSUE 13 • JUNE 2012
European Industrial Pharmacy
Editorial Comment
Gino Martini

Severe drug shortages – Who’s to blame?
Michael Anisfeld
What happens to the patient when quality oversight is deficient at many levels.

GI tract challenges
Emma L McConnell, Hywel D Williams and Samuel R Pygall
The GI tract forms a challenging obstacle course for medicines. It is therefore important to understand the factors that can affect drug release.

Stability of omeprazole oral preparations
MG Lee, AJ Charvill, S Young, HL Douglas and S Matumo
This study revealed a defect in the dissolution of an omeprazole product that led to its reformulation and a revision of the British Pharmacopoeia’s dissolution test.

The safety of excipients used in medicines for children
Jennifer Walsh
A key consideration for those formulating paediatric medicines.

Survey of pharmaceutical education in Europe
Jeffrey Atkinson, Jane Nicholson and Bart Rombaut
PHARMINE – Report on the integration of the industry component in pharmacy education and training.

Book Review

Regulatory Review
Malcolm Holmes

News From The EIPG
Jane Nicholson

Events

Read Issue 13   

ISSUE 12 • MARCH 2012
European Industrial Pharmacy
Editorial Comment
Gino Martini

The breast implant scandal and European medical device regulation
Maria Donawa and Roger Gray
The circumstances of the recent breast implant scandal are described in detail and the actions needed to prevent it in future are discussed.

The role of pharmacists in the clinical supply chain for drug development
Wyndi Phillips
There are major benefits of including a pharmacist in the clinical supply chain.

Pharmaceutical quality by design
Walkiria Schlindwein
Rationale and details of a new accredited distance learning postgraduate course.

Evolution of the Japanese regulatory system
David Jeffreys
A new approach to healthcare product regulation, the Pharmaceuticals and Medical Devices Agency (PMDA),was established in Japan in 2004. This article outlines the current situation.

The Falsified Medicines Directive – impact on wholesalers
Monika Derecque-Pois
The new directive specifies that wholesalers need to check the safety features on the outer packaging. However, this could cause them major problems that would also affect manufacturers, pharmacies and patients.

The Falsified Medicines Directive – the Swedish way
Anita Finne-Grahnén
A system of coding and identifying products throughout the entire chain is being introduced in Europe following the publication of the Falsified Medicines Directive in 2011. A Swedish pilot study has shown the way.

Book Review

Regulatory Review
Malcolm Holmes

News From The EIPG
Jane Nicholson

Events

Read Issue 12   

ISSUE 11 • DECEMBER 2011
European Industrial Pharmacy
Editorial Comment
Gino Martini

Placing excipients at the heart of safe medicines
Iain Moore and Flavia Arce
In the absence of comprehensive EU regulations, industry groups are developing their own GMP/GDP principles for excipients.

Progression in tablet compression
Dale Natoli
Although many attempts have been made to make tablet compression a scientific study, fast consistent production of high-quality tablets can still be considered an art rather than a science.

Spray dried biodegradable polymers for controlled drug delivery systems
Cordin Arpagaus and Nina Schafroth
Various process parameters were used to compare the morphology of different biogradable polymers in order to demonstrate the production of microspheres for controlled drug delivery using a mini spray dryer.

Lost in translation? When patient information crosses borders
Inger Askehave and Karen Korning Zethsen
Whereas technical translations generally pose few problems, translation of Patient Information Leaflets (PILs) from English into other European languages needs specific expertise.

Challenges faced by companion diagnostics
Kenneth P Krul
Three major issues are holding back rapid growth in the market: greater cost than standard therapies, reduction of the doctor’s choice and protection of patient’s privacy.

Book Review

Regulatory Review
Malcolm Holmes

Pharmaceutical Forum

News From The EIPG
Jane Nicholson

Events

Read Issue 11   

ISSUE 10 • SEPTEMBER 2011
European Industrial Pharmacy
Editorial Comment
Gino Martini

Wicked problems
Nassir Hussain and Tom Ritchey
The technique of General Morphological Analysis provides a virtual model for complex, apparently insoluble “wicked problems” that are normally difficult to define and structure.

Towards a European patent litigation solution
Gareth Williams and Graham Burnett-Hall
Intellectual property protection is now harmonised throughout most of Europe but there is still disagreement in setting up a central court to deal with infringements.

Achieving cleanliness in medical engineering
Doris Schulz
Modern cleaning processes for medical instruments, devices and implants are described and discussed.

The challenges of bacteriophage therapy
Alexander Sulakvelidze
Bacteriophages should now be considered as possible alternatives to antibiotics providing that technical and non-technical problems can be overcome.

Innovation – science or art?
Robert Bates and Anna Bruns
Willingness to innovate is a key factor in the development of a successful drug discovery unit.

Book Reviews

Regulatory Review
Malcolm Holmes

Pharmaceutical Forum

News From The EIPG
Jane Nicholson

Events

Read Issue 10   

ISSUE 9 • JUNE 2011
European Industrial Pharmacy
Editorial Comment
Gino Martini

Formulation and delivery of cannabinoids
Mark Rogerson
The poor solubility of cannabinoids led GW Pharmaceuticals to develop an oral spray delivery system.

Pharmaceutical industry’s perspective on switches and its relationship with the pharmacy/pharmacist
Mafalda Martins
Reclassifying a medicine is becoming more widely accepted but there are challenges of trust to consider.

Social media in life sciences
Mary Canady
A powerful and ultimately essential marketing took to help small and large companies alike to build relationships with their customers.

Bacterial bile acid modification and potential pharmaceutical applications
Brian V Jones
Manipulation of bacterial bile acid metabolism could lead to a number of opportunities in disease prevention and treatment.

Novel zero-saccharide orally disintegrating tablets
Farhan AlHusban and Afzal R Mohammed
The saccharide mannitol is commonly used as an excipient in the formulation of orally disintegrating tablets. This study investigates some amino acids as possible non-saccharide alternatives.

Reaching the tipping point: pharmaceuticals out of balance
Jonathan Anscombe and Michael Thomas
This report by the international consultants, AT Kearney, argues that the traditional model of a global pharmaceutical industry will struggle to survive and will need to shift from being R&D-driven to market-driven.

Regulatory Review
Malcolm Holmes

News From The EIPG
Jane Nicholson

Pharmaceutical Forum

Dates For Your Diary

Read Issue 9   

ISSUE 8 • FEBRUARY 2011
European Industrial Pharmacy
Editorial Comment
Gino Martini

Solid oral dosage forms for children – formulations, excipients and acceptance issues
Ines Stoltenberg, Gesine Winzenburg and Jörg Breitkreutz
New solid oral dosage forms for paediatric use have advantages over liquids but their acceptability needs to be demonstrated and the excipients need to be carefully chosen for the various age groups.

The role of calorimetry – in the development of drug delivery systems
Simon Gaisford
The techniques of differential scanning and isothermal calorimetry offer unique benefits for the analysis of pharmaceuticals, especially in the development of formulations and in drug delivery systems.

Sodium content of effervescent analgesics
Ingo Friedrich, Alfred Bonatz and Karla Schwenke
An analysis of some common paracetamol-containing effervescent analgesics shows a wide variation in sodium content.

DataMatrix adopted by French pharmaceutical industry
Frédéric Lemaire
France becomes one of the first European countries to adopt the DataMatrix barcode system in order to improve control of the supply chain.

Chlorhexidine: skin permeation and antisepsis
Tarja J Karpanen, Emma R Hendry, Tony Worthington, Peter A Lambert and Barbara R Conway
This study from Aston University shows that skin penetration and antimicrobial efficiency of chlorhexidine can be enhanced by combining it with eucalyptus oil.

Regulatory Review
Malcolm Holmes

News From The EIPG
Jane Nicholson

Pharmaceutical Forum

Dates For Your Diary

Read Issue 8